Compare NBIX & PAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBIX | PAA |
|---|---|---|
| Founded | 1992 | 1981 |
| Country | United States | United States |
| Employees | N/A | 4200 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Natural Gas Distribution |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 15.8B |
| IPO Year | 1996 | N/A |
| Metric | NBIX | PAA |
|---|---|---|
| Price | $158.25 | $22.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 13 |
| Target Price | ★ $180.91 | $21.83 |
| AVG Volume (30 Days) | 1.2M | ★ 3.1M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 7.38% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $24.73 | $9.51 |
| Revenue Next Year | $13.14 | N/A |
| P/E Ratio | $83.53 | ★ $12.39 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $117.84 | $15.69 |
| 52 Week High | $162.39 | $23.04 |
| Indicator | NBIX | PAA |
|---|---|---|
| Relative Strength Index (RSI) | 75.63 | 62.02 |
| Support Level | $125.54 | $20.83 |
| Resistance Level | $158.92 | N/A |
| Average True Range (ATR) | 4.50 | 0.53 |
| MACD | 2.55 | 0.03 |
| Stochastic Oscillator | 89.50 | 89.74 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Plains All American Pipeline LP, through its subsidiaries, engages in the pipeline transportation, terminaling, storage, and gathering of crude oil and natural gas liquids (NGL) in the United States and Canada. The company operates through two segments, Crude Oil and NGL. The Crude Oil segment offers gathering and transporting crude oil through pipelines, gathering systems, trucks, barges, or railcars. The NGL segment is involved in natural gas processing and NGL fractionation, storage, transportation, and terminalling. It generates the majority of its revenue from the Crude Oil segment.